Cargando…

Improved disease activity with fosdagrocorat (PF‐04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study

AIM: To assess efficacy and safety of fosdagrocorat (PF‐04171327), a potential dissociated agonist of the glucocorticoid receptor, in rheumatoid arthritis (RA) patients. METHODS: This multicenter, double‐blind, parallel‐group, active‐ and placebo‐controlled Phase 2 study (NCT00938587) randomized 86...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stock, Thomas, Fleishaker, Dona, Wang, Xin, Mukherjee, Arnab, Mebus, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084298/ https://www.ncbi.nlm.nih.gov/pubmed/28328159 http://dx.doi.org/10.1111/1756-185X.13053

Ejemplares similares

Population Pharmacokinetics of Fosdagrocorat (PF‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis
por: Weatherley, Barry, et al.
Publicado: (2017)

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study
por: Buttgereit, Frank, et al.
Publicado: (2019)

In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF‐00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor
por: Ripp, Sharon L., et al.
Publicado: (2017)

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
por: Fleishaker, Dona L, et al.
Publicado: (2012)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study
por: Fleishaker, Dona L., et al.
Publicado: (2016)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics
por: Shoji, S, et al.
Publicado: (2017)

Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis
por: Venter, Gabriella, et al.
Publicado: (2021)

Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis
por: van Oosten, Manon JM, et al.
Publicado: (2010)

In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis
por: Quax, Rogier AM, et al.
Publicado: (2012)

Glucocorticoid receptor gene polymorphisms and susceptibility to rheumatoid arthritis
por: Donn, Rachelle, et al.
Publicado: (2007)

Why and how to optimize glucocorticoid treatment in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2012)

The use of glucocorticoids in rheumatoid arthritis - no 'rational' approach yet
por: Desai, Sonali P, et al.
Publicado: (2010)

Glucocorticoids in rheumatoid arthritis: current status and future studies
por: Hua, Charlotte, et al.
Publicado: (2020)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2016)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
por: Mease, Philip J., et al.
Publicado: (2023)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis
por: Makrygiannakis, Dimitrios, et al.
Publicado: (2012)

Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
por: Verhoeven, Frank, et al.
Publicado: (2016)

Glucocorticoid management in rheumatoid arthritis: morning or night low dose?
por: Paolino, Sabrina, et al.
Publicado: (2017)

292 Fibromyalgianess and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis
por: Wallace, Beth, et al.
Publicado: (2022)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Viewpoint: Glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider
por: Boers, Maarten
Publicado: (2023)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2022)

Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy
por: Aeberli, Daniel, et al.
Publicado: (2013)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis
por: Honne, Kyoko, et al.
Publicado: (2015)

Rheumatoid arthritis - a neuroendocrine immune disorder: glucocorticoid resistance, relative glucocorticoid deficiency, low-dose glucocorticoid therapy, and insulin resistance
por: Straub, Rainer H
Publicado: (2014)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016)

Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis
por: Quax, R. A. M., et al.
Publicado: (2015)

Cannabinoid Receptor 2 Agonist JWH-015 Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts and in Adjuvant Induced Arthritis Rat via Glucocorticoid Receptor
por: Fechtner, Sabrina, et al.
Publicado: (2019)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Monocytes are essential for inhibition of synovial T-cell glucocorticoid-mediated apoptosis in rheumatoid arthritis
por: Makrygiannakis, Dimitrios, et al.
Publicado: (2008)

Thyroid Storm Masked by Hemodialysis and Glucocorticoid Therapy in a Patient with Rheumatoid Arthritis
por: Sasaki, Yohei, et al.
Publicado: (2012)

Proper time to initiate antiosteoporotic treatment in rheumatoid arthritis with or without glucocorticoid use
por: Lee, Sang-Won
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aeibrmi17m72fcq1rp5trhc55m